Katherine Harris

This inventor holds 17 USPTO granted patents and 26 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Teneobio, Inc., Teneoone, Inc., Teneotwo, Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katherine Harris. Retrieved from https://idiyas.com/inventor/katherine-harris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 26)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 20)

EPO Patents = 4 (Patent Applications = 23)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Newark, CA (US) (2021 - 2024)
Fremont, CA (US) (2022 - 2024)
Thousand Oaks, CA (US) (2024)

Company Filing History:

Arsenal Biosciences, Inc.

patents

5. 1 out of 1

The United States of America, as Represented by the Secretary, Department of Health and Human

patent

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747298 - MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA (2026-09-29),

2. 12735503 - ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES (2026-09-15),

3. 12709644 - ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES (2026-08-18),

4. 12590163 - AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE (2026-03-31),

5. 12570717 - ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS (2026-03-10),

6. 12371505 - Anti-BCMA heavy chain-only antibodies (2025-07-29),

7. 12202898 - Heavy chain antibodies binding to CD19 (2025-01-21),

8. 12037407 - Immune cells having co-expressed shRNAS and logic gate systems (2024-07-16),

9. 11970540 - Anti-BCMA heavy chain-only antibodies (2024-04-30),

10. 11884735 - Agonistic anti-IL-2R antibodies and methods of use (2024-01-30),

11. 11873336 - Heavy chain antibodies binding to CD22 (2024-01-16),

12. 11613572 - CD3 binding antibodies (2023-03-28),

13. 11505606 - CD3 binding antibodies (2022-11-22),

14. 11434299 - Anti-BCMA heavy chain-only antibodies (2022-09-06),

15. 11421027 - CD3 binding antibodies (2022-08-23),

Title: Innovations of Katherine Harris

Introduction

Katherine Harris is a prominent inventor based in Newark, CA, known for her significant contributions to the field of biotechnology. With a total of 12 patents to her name, she has made remarkable advancements in the treatment of B-cell disorders.

Latest Patents

Her latest patents include the development of Anti-BCMA heavy chain-only antibodies, which are designed to treat B-cell disorders characterized by the expression of BCMA. These patents disclose methods for making such antibodies, as well as compositions, including pharmaceutical formulations, that utilize these antibodies. Additionally, she has developed heavy chain antibodies binding to CD19, known as Anti-CD19 heavy chain antibodies, which are also aimed at treating B-cell disorders characterized by CD19 expression.

Career Highlights

Katherine has worked with notable companies such as Teneobio, Inc. and Teneotwo, Inc., where she has played a crucial role in advancing innovative therapies. Her work has been instrumental in the development of new treatments that address critical health challenges.

Collaborations

Throughout her career, Katherine has collaborated with esteemed colleagues, including Nathan D Trinklein and Wim Van Schooten, contributing to a dynamic research environment that fosters innovation.

Conclusion

Katherine Harris stands out as a leading inventor in the biotechnology sector, with her groundbreaking patents and collaborations paving the way for future advancements in medical treatments. Her work continues to impact the field significantly.

Profile summary based on public USPTO records.